News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
Pharmaceutical industry
The epic inside story of long-term criminal fraud at Ranbaxy, the Indian drug company that made generic ARVs

The confidential report laid bare systemic fraud in Ranbaxy's worldwide regulatory filings. It found that "the majority of products filed in Brazil, Mexico, Middle East, Russia, Romania, Myanmar, Thailand, Vietnam, Malaysia, African Nations, have data submitted which did not exist or data from different products and from different countries ..."

Published
17 May 2013
From
Fortune
Access to medicines and treatment
India: Patents and precedents

Pharmaceutical companies fear that the battle raging in India over patents will inspire other countries to change their laws.

Published
16 May 2013
From
Financial Times
Pharmaceutical industry
Analysis: Drugmakers face more scrutiny of discordant U.S. prices

The world's biggest drug makers have for years enjoyed rich premiums for their medicines in the U.S. market. Those days may be coming to an end.

Published
13 May 2013
From
Reuters
Access to medicines and treatment
Stockout Risks of South Africa’s New ARV Programme

It is South Africa's shaky ARV supply track record that has treatment activists sounding alarm bells over the Apr. 1 introduction of fixed-dose ARVs (FDAs). “With the individual ARV drugs, if there is a shortage of one ARV then people can still take the other two drugs, though it’s not ideal. However, if there’s a stockout of the fixed-dose pill, then patients will have no recourse,” Mark Heywood, executive director of health and social justice advocacy group Section 27, tells IPS.

Published
07 May 2013
From
Inter Press Service
HIV treatment in children
Patients in Control: Protest action in Russia - the lives of HIV-positive children are not profitable for distributors

A protest action organized by activists of "Patients in Control" took place in Moscow in front of the office of the largest distributor of ARV medications in Russia ("R-Pharm"). The activists were outraged about the fact that around 20 auctions for antiretrovirals in different regions did not take place because no bids were submitted; half of those tenders were for paediatric formulations.

Published
03 May 2013
From
EATG
Pharmaceutical industry
Gilead Sciences Reports Higher Sales, FDA Letter

Gilead Sciences Inc.'s (GILD) first-quarter sales rose a disappointing 8.4% as increased traction for the newer additions to the company's HIV franchise wasn't enough to offset customers stocking up on its antiviral drugs ahead of price increases implemented earlier this year.

Published
03 May 2013
From
Wall Street Journal
Pharmaceutical industry
Gilead profit rises 63 pct, sales of older HIV drugs dip

Sales of HIV drug Atripla fell 1 percent to $877.1 million, while sales of another older product, Truvada, fell 8 percent to $700.2 million. Sales of newer HIV drug Complera rose 184 percent, and recently launched Stribild had sales of $92.1 million.

Published
03 May 2013
From
Reuters
Clinical trials
Health NGO pushes for more transparency in clinical trials

The European Commission's proposed revision on the Clinical Trials Directive is an important step forward, but does not go far enough, says the Cochrane Collaboration, a healthcare NGO which advocates more transparency in clinical trials.

Published
02 May 2013
From
EurActiv.com
Pharmaceutical industry
Pharmaceutical Industry: The Doctor’s Dilemma

By law medical professionals must keep up their education — providing plenty of opportunities for wealthy pharmaceutical companies to help out. But do free flights, consultancy fees, free dinners and free conferences put doctors in Big Pharma’s pocket?

Published
01 May 2013
From
The Global Mail
Pharmaceutical industry
Johnson & Johnson allies with biotech startup on HIV drug in China

The biopharma startup Ascletis has snagged exclusive rights from Johnson & Johnson's ($JNJ) Janssen for an experimental HIV protease inhibitor for the China market. Hangzhou, China-based Ascletis aims to develop the candidate, called TMC310911.

Published
01 May 2013
From
FierceBiotech
← First12345...53Next →

Filter by country